N
OCUL icon

Natixis’s Ocular Therapeutix OCUL Stock Holding History

Natixis’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
+11,880
New +$108K ﹤0.01% 985

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Natixis's OCUL Position: Q2 2026 in Review

Natixis opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 11,880 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #985 among its holdings.

261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Natixis held 11,880 shares of Ocular Therapeutix worth $117K as of Q2 2026.
  • Ocular Therapeutix was a new Natixis position in Q2 2026.
  • Ocular Therapeutix made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #985 holding.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.